{"product_id":"antibody-mediated-drug-delivery-systems-isbn-9780470612811","title":"Antibody-Mediated Drug Delivery Systems","description":"This book covers various aspects of antibody mediated drug delivery systems – theoretical aspects, processing, viral and non-viral vectors, and fields where these systems find and \/or are being evaluated for applications as therapeutics and diagnostic treatment. Chapters discuss actual applications of techniques used for formulation and characterization. Applications areas include cancer, pulmonary, ocular diseases; brain drug delivery; and vaccine delivery. The contributing authors represent over 10 different countries, covering recent developments happening around the globe.  \u003cp\u003eCONTRIBUTORS xv\u003c\/p\u003e \u003cp\u003ePREFACE xix\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 1 ANTIBODY-MEDIATED DRUG DELIVERY SYSTEMS: GENERAL REVIEW AND APPLICATIONS\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eNavdeep Kaur, Karthikeyan Subramani, and Yashwant Pathak 1\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Historical Perspective 1\u003c\/p\u003e \u003cp\u003e2 Antibodies 2\u003c\/p\u003e \u003cp\u003e3 Antibody Mediation 3\u003c\/p\u003e \u003cp\u003e4 Antibody-Mediated Drug Delivery Systems 4\u003c\/p\u003e \u003cp\u003e5 Applications 6\u003c\/p\u003e \u003cp\u003e6 Recent Trends 9\u003c\/p\u003e \u003cp\u003e7 Future Trends 10\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 2 IMMUNOLIPOSOMES FOR CARDIOVASCULAR TARGETING\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eTatyana Levchenko, William Hartner, and Vladimir P. Torchilin 13\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 13\u003c\/p\u003e \u003cp\u003e2 Immunoliposome Targeting to Pathological Regions of the Vessel Wall 14\u003c\/p\u003e \u003cp\u003e3 Liposome Internalization by Endothelial Cells 15\u003c\/p\u003e \u003cp\u003e4 Targeting of Atherosclerotic Lesions for Tomographic Imaging 17\u003c\/p\u003e \u003cp\u003e5 Antibody-Mediated Liposomes for Diagnosis of Thrombosis 17\u003c\/p\u003e \u003cp\u003e6 Thrombolytic Therapy with Immunoliposomes 18\u003c\/p\u003e \u003cp\u003e7 Targeted Sealing of Cell Membrane Lesions: Preservation of Cell Viability 19\u003c\/p\u003e \u003cp\u003e8 Accumulation of Liposomes and Immunoliposomes in the Ischemic Heart 21\u003c\/p\u003e \u003cp\u003e9 Immunoliposomes as a Drug and Gene Delivery Vehicle to the Infarcted Heart 26\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 3 ANTIBODY-MEDIATED DRUG DELIVERY SYSTEMS FOR BREAST CANCER THERAPEUTICS\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eLeonor Munoz Alcivar and Yashwant Pathak 35\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 35\u003c\/p\u003e \u003cp\u003e2 Breast Cancer 35\u003c\/p\u003e \u003cp\u003e3 Drug Delivery Systems 36\u003c\/p\u003e \u003cp\u003e4 Monoclonal Antibodies 37\u003c\/p\u003e \u003cp\u003e5 Human Epidermal Growth Factor Receptor 2 40\u003c\/p\u003e \u003cp\u003e6 Antibody-Mediated Drug Delivery System 43\u003c\/p\u003e \u003cp\u003e7 Targets for the Treatment of Breast Cancer 45\u003c\/p\u003e \u003cp\u003e8 Breast Cancer Therapies 46\u003c\/p\u003e \u003cp\u003e9 The Future of Breast Cancer Therapeutics 49\u003c\/p\u003e \u003cp\u003e10 Other Treatment Strategies 50\u003c\/p\u003e \u003cp\u003e11 Nanotechnology 51\u003c\/p\u003e \u003cp\u003e12 Conclusions 52\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 4 DEVELOPMENT OF IMMUNONCONJUGATES FOR IN VIVO DELIVERY: CANCER DIAGNOSIS, IMAGING, AND THERAPY\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eArutselvan Natarajan 57\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 57\u003c\/p\u003e \u003cp\u003e2 Immunoconjugates 61\u003c\/p\u003e \u003cp\u003e3 Immunoconjugates in Cancer Therapy 62\u003c\/p\u003e \u003cp\u003e4 Immunoconjugates for Imaging 69\u003c\/p\u003e \u003cp\u003e5 Immunoconjugates in Diagnostic Applications 71\u003c\/p\u003e \u003cp\u003e6 Immunoconjugates’ Promising Future and Challenges 72\u003c\/p\u003e \u003cp\u003e7 Summary 73\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 5 MATHEMATICAL MODELS OF ANTI-TNF THERAPIES AND THEIR CORRELATION WITH TUBERCULOSIS\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eSimeone Marino, Mohammad Fallahi-Sichani, Jennifer J. Linderman, and Denise E. Kirschner 83\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 83\u003c\/p\u003e \u003cp\u003e2 Tuberculosis, TNF, and Anti-TNF Drugs 84\u003c\/p\u003e \u003cp\u003e3 Theoretical Models To Study TB Infection 88\u003c\/p\u003e \u003cp\u003e4 Present and Future Work 96\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 6 TARGETED NANOPARTICLES IN RADIOTHERAPY\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eMisty Muscarella and Yashwant Pathak 105\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 105\u003c\/p\u003e \u003cp\u003e2 Nanoparticles 106\u003c\/p\u003e \u003cp\u003e3 Radiotherapy 110\u003c\/p\u003e \u003cp\u003e4 Nanoparticles in Radiotherapy 111\u003c\/p\u003e \u003cp\u003e5 Current and Future Developments with Nanotechnology in Radiotherapy 123\u003c\/p\u003e \u003cp\u003e6 Conclusions 124\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 7 ELECTRICALLY-ENHANCED DELIVERY OF DRUGS AND CONJUGATES FOR CANCER TREATMENT\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eArutselvan Natarajan, Luca Campana, and Raji Sundararajan 129\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 129\u003c\/p\u003e \u003cp\u003e2 Electroporation Mechanisms to Permeabilize the Drugs and DNAs in Cells 130\u003c\/p\u003e \u003cp\u003e3 Electroporation-Aided Drug Delivery for Preclinical Studies 133\u003c\/p\u003e \u003cp\u003e4 EP applications for Human Patient Studies 136\u003c\/p\u003e \u003cp\u003e5 Future Perspectives 138\u003c\/p\u003e \u003cp\u003e6 Summary 139\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 8 CHARACTERIZATION OF MONOCLONAL ANTIBODY VARIANTS AND GLYCOSYLATION\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eTing Zheng, Srinivasa Rao, Jeff Rohrer, and Chris Pohl 145\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Characterization of Monoclonal Antibody Heterogeneity by HPLC Analysis 145\u003c\/p\u003e \u003cp\u003e2 Analysis of Monoclonal Antibody Glycosylation 150\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 9 ANTIBODY-MEDIATED DRUG DELIVERY SYSTEM FOR LYMPHATIC TARGETING TREATMENT\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eFang Wu, Hong Ding, and Zhirong Zhang 169\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 169\u003c\/p\u003e \u003cp\u003e2 Lymphatic Disorders and Their Normal Treatment 170\u003c\/p\u003e \u003cp\u003e3 Antibody-Mediated Drug Delivery Systems for Lymphatic Targeting Treatment 172\u003c\/p\u003e \u003cp\u003e4 Conclusions and Future Perspectives 183\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 10 METHODS FOR NANOPARTICLE CONJUGATION TO MONOCLONAL ANTIBODIES\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJunling Li and Chin K. Ng 191\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 191\u003c\/p\u003e \u003cp\u003e2 Current Nanoparticle Systems used for Conjugation with mAbs 191\u003c\/p\u003e \u003cp\u003e3 Conjugation Methods 192\u003c\/p\u003e \u003cp\u003e4 Conclusions 202\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 11 SINGLE-USE SYSTEMS IN ANIMAL CELL–BASED BIOPRODUCTION\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eWilliam G. Whitford 209\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 209\u003c\/p\u003e \u003cp\u003e2 Component Offerings 214\u003c\/p\u003e \u003cp\u003e3 Characteristics of Single-Use Systems and Their Applications 218\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 12 IMMUNOLIPOSOMES FOR SPECIFIC DRUG DELIVERY\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eManuela Calin 229\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction: Advances in Liposome Formulation 229\u003c\/p\u003e \u003cp\u003e2 Design of Immunoliposomes for Site-Specific Drug Delivery 230\u003c\/p\u003e \u003cp\u003e3 Cellular-Specific Targeting of Immunoliposomes 242\u003c\/p\u003e \u003cp\u003e4 Cellular-Specific Internalization of Immunoliposomes 246\u003c\/p\u003e \u003cp\u003e5 Immunoliposomes in Diagnosis and Therapy 247\u003c\/p\u003e \u003cp\u003e6 Clinical Use of Immunoliposomes 251\u003c\/p\u003e \u003cp\u003e7 Conclusions and Perspectives 252\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 13 GENE THERAPY TARGETING KIDNEY DISEASES: ROUTES AND VEHICLES\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eYoshitaka Isaka, Yoshitsugu Takabatake, and Hiromi Rakugi 267\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 267\u003c\/p\u003e \u003cp\u003e2 Rationale for Successful Gene Targeting 268\u003c\/p\u003e \u003cp\u003e3 Site-Specific Gene Delivery 268\u003c\/p\u003e \u003cp\u003e4 Nuclear Import of Gene Material 270\u003c\/p\u003e \u003cp\u003e5 Targeting the Glomerulus 270\u003c\/p\u003e \u003cp\u003e6 Targeting the Tubule 272\u003c\/p\u003e \u003cp\u003e7 Targeting the Interstitium 274\u003c\/p\u003e \u003cp\u003e8 Targeting Muscle 274\u003c\/p\u003e \u003cp\u003e9 Conclusions 275\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 14 DETECTION OF ANTIBODIES TO POLY(ETHYLENE GLYCOL) POLYMERS USING DOUBLE-ANTIGEN-BRIDGING IMMUNOGENICITY ELISA\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eYijuan Liu, Helen Reidler, Jing Pan, David Milunic, Dujie Qin, Dave Chen, Yli Remo Vallejo, and Ray Yin 279\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 279\u003c\/p\u003e \u003cp\u003e2 Methods 280\u003c\/p\u003e \u003cp\u003e3 Results 283\u003c\/p\u003e \u003cp\u003e4 Discussion 286\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 15 ANTIBODIES IN NANOMEDICINE AND MICROIMAGING METHODS\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eRakesh Sharma 291\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction: Antibody Molecules and Nanoparticles 291\u003c\/p\u003e \u003cp\u003e2 Antibody-Based Nanoparticles in Microimaging 292\u003c\/p\u003e \u003cp\u003e3 Troponin T: Newer Magnetic Immunoassay Method 317\u003c\/p\u003e \u003cp\u003e4 Gold Nanoparticles as an Antigen Carrier and Adjuvant 330\u003c\/p\u003e \u003cp\u003e5 Immunochemical Biosensors, Nanomedicine, and Disease 339\u003c\/p\u003e \u003cp\u003e6 Future Directions and Conclusions 341\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 16 METHODS FOR POLYMERIC NANOPARTICLE CONJUGATION TO MONOCLONAL ANTIBODIES\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eUyen Minh Le, Hieu Tran, and Yashwant Pathak 351\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 351\u003c\/p\u003e \u003cp\u003e2 Conjugation of mAb and Polyethylenimine Nanoparticles 353\u003c\/p\u003e \u003cp\u003e3 Conjugation of mAb to Poly(Lactide-CO-Glycolide) Nanoparticles 357\u003c\/p\u003e \u003cp\u003e4 Conjugation of mAb to Poly(Lactic Acid) and its Derivatives 359\u003c\/p\u003e \u003cp\u003e5 Conjugation of mAb to Other Polymeric Nanoparticles 360\u003c\/p\u003e \u003cp\u003e6 Summary 361\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 17 PLANT-DERIVED ANTIBODIES FOR ACADEMIC, INDUSTRIAL, AND THERAPEUTIC APPLICATIONS\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eSlavko Komarnytsky and Nikolai Borisjuk 365\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Historical Perspective 365\u003c\/p\u003e \u003cp\u003e2 Plant-Based Production of Recombinant Proteins 366\u003c\/p\u003e \u003cp\u003e3 Expression in an Entire Plant Versus a Plant Organ 367\u003c\/p\u003e \u003cp\u003e4 ER Targeting and Secretion of Recombinant Proteins 368\u003c\/p\u003e \u003cp\u003e5 Expression in Seeds 370\u003c\/p\u003e \u003cp\u003e6 Transient Expression 371\u003c\/p\u003e \u003cp\u003e7 Glycosylation 373\u003c\/p\u003e \u003cp\u003e8 Recent Examples of Plant-Derived Antibodies Effective in Mammalian Systems 375\u003c\/p\u003e \u003cp\u003e9 Conclusions 376\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 18 MONOCLONAL ANTIBODIES AS BIOPHARMACEUTICALS\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eGirish J. Kotwal 383\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Historical Perspective 383\u003c\/p\u003e \u003cp\u003e2 Introduction 384\u003c\/p\u003e \u003cp\u003e3 Structure and Types of mAbs 385\u003c\/p\u003e \u003cp\u003e4 Mechanism of Action 385\u003c\/p\u003e \u003cp\u003e5 FDA-approved mAb Biopharmaceuticals in Current Use 386\u003c\/p\u003e \u003cp\u003e6 Future of Monoclonal Antibodies as Biopharmaceuticals 389\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 19 PULMONARY TARGETING OF NANOPARTICLES AND MONOCLONAL ANTIBODIES\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eWeiyuan Chang 391\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 391\u003c\/p\u003e \u003cp\u003e2 Attributes of mAbs as Therapeutics for Pulmonary Diseases 392\u003c\/p\u003e \u003cp\u003e3 Antibody-Conjugated Nanoparticles for Lung Targeting 393\u003c\/p\u003e \u003cp\u003e4 Monoclonal Antibodies in the Treatment of Asthma 394\u003c\/p\u003e \u003cp\u003e5 Monoclonal Antibodies in the Treatment of COPD 398\u003c\/p\u003e \u003cp\u003e6 Challenges in Pulmonary Disease 400\u003c\/p\u003e \u003cp\u003e7 Conclusions 402\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 20 ANTIBODY-MEDIATED ARTHRITIS AND NEW THERAPEUTIC AVENUES\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eKutty Selva Nandakumar 407\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Autoantibodies in Rheumatoid Arthritis 407\u003c\/p\u003e \u003cp\u003e2 Role of Cartilage Antigen-Specific Antibodies in Inducing Arthritis 408\u003c\/p\u003e \u003cp\u003e3 Arthritis Mediation Through Antibodies Recognizing Citrullinated Antigens 413\u003c\/p\u003e \u003cp\u003e4 Regulation at the Effector Level 414\u003c\/p\u003e \u003cp\u003e5 Cartilage Damage Independent of Inflammatory Mediators 414\u003c\/p\u003e \u003cp\u003e6 pathogenicity of GPI-Specific Antibodies 415\u003c\/p\u003e \u003cp\u003e7 Therapeutic Cleavage of Arthritogenic Antibodies 415\u003c\/p\u003e \u003cp\u003e8 Arthritis Attenuation Though Removal of Specific Sugars on IgG 417\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 21 IMMUNONANOPARTICLES FOR NUCLEAR IMAGING AND RADIOTHERAPY\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eOren Giladi and Simon Benita 427\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Radioisotopes and Radiopharmaceuticals 427\u003c\/p\u003e \u003cp\u003e2 Radiolabeled Antibodies 432\u003c\/p\u003e \u003cp\u003e3 Radiolabeled Nanoparticles 437\u003c\/p\u003e \u003cp\u003e4 Future Perspectives and Conclusions 449\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 22 MONOCLONAL ANTIBODIES IN THE TREATMENT OF ASTHMA\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eGlenn J. Whelan 457\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 457\u003c\/p\u003e \u003cp\u003e2 IgE 458\u003c\/p\u003e \u003cp\u003e3 TNFα 460\u003c\/p\u003e \u003cp\u003e4 IL-5 462\u003c\/p\u003e \u003cp\u003e5 IL-9 464\u003c\/p\u003e \u003cp\u003e6 IL-4 and IL-13 465\u003c\/p\u003e \u003cp\u003e7 Targeting the T-cell 467\u003c\/p\u003e \u003cp\u003e8 Conclusions 468\u003c\/p\u003e \u003cp\u003eReferences 469\u003c\/p\u003e \u003cp\u003e\u003cb\u003eINDEX 473\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eYashwant Pathak\u003c\/b\u003e, PhD, is the Associate Dean for Faculty Affairs at the College of Pharmacy, University of South Florida, Tampa, Florida. Dr. Pathak studied pharmaceutical technology at Nagpur University, India, and conflict management at Sullivan University, Kentucky. With extensive experience in academia as well as industry, he has more than 100 publications, abstracts, and reviews, two patents, five books on nanotechnology, and two books on nutraceuticals to his credit. His areas of research include drug delivery systems and their characterization in animal models.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSimon Benita\u003c\/b\u003e, PhD, is Head of the School of Pharmacy, Director of the Institute for Drug Research, and Professor of the Faculty of Medicine at The Hebrew University of Jerusalem. He holds twenty-two patents and has written 143 journal papers and seventeen book chapters. Dr. Benita has also edited three other books.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eA comprehensive guide to the concepts, technology, and applications of antibody-mediated drug delivery systems\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eAntibody-Mediated Drug Delivery Systems: Concepts, Technology, and Applications\u003c\/i\u003e provides readers with comprehensive coverage of one of the fastest growing fields of pharmaceutical and biotechnology research. An up-to-date, practical reference on the essential ideas, analytical developments, processing, and utilization of antibody-mediated drug delivery systems, this edited volume features contributions from acclaimed experts from around the globe.\u003c\/p\u003e \u003cp\u003eEach of the twenty-two chapters explores the opportunities, challenges, and uses of antibody-mediated delivery systems for generating novel therapeutic treatments. Topics covered include targeted treatments for cancer, cardiovascular diseases, asthma, and other conditions, as well as brain drug delivery, vaccine delivery, plant-derived antibodies, gene therapy, and more.\u003c\/p\u003e \u003cp\u003eSix of the ten bestselling drugs on the market today are therapeutic antibodies, yet no definitive and detailed review of current developments in the field has been published since 1988. \u003ci\u003eAntibody-Mediated Drug Delivery Systems\u003c\/i\u003e fills this hole in the literature, with insightful coverage of the full spectrum of essential concepts, technologies, and applications of these treatments, making it an essential resource for medical and scientific researchers and students working in industry and academia.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47988745437413,"sku":"NP9780470612811","price":184.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470612811.jpg?v=1761781423","url":"https:\/\/k12savings.com\/products\/antibody-mediated-drug-delivery-systems-isbn-9780470612811","provider":"K12savings","version":"1.0","type":"link"}